Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — Novozymes — Q1 2021 Earnings Presentation
12 slides from Novonesis A/s Class B's earnings presentation, Apr 27, 2021
Slide 1: Conference call Q1 2021
Conference call Q1 2021 April 27, 2021
Slide 2: Forward Looking Statement
Disclaimer Forward Looking Statement This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limite
Slide 3: Highlights
Latest results Highlights Q1 2021 Q1 2020 Stronger-than-expected start to the year; 3% organic sales growth and strong Realized Realized earnings. 2021 outlook maintained Sales performance, organic % 3 10 • Organic Q1 sales y/y: 3%. EBIT margin % 29.6 28.9 • Better-than-expected performance due to c
Slide 4: Household Care 33% of sales
Latest results Household Care Growth above expectations mainly due to timing, especially in 2021 perspectives emerging markets • Enzyme penetration in emerging markets • Organic Q1 sales y/y: 2%. • Freshness rollout with broad market launch • Penetration in emerging markets and the rollout of the •
Slide 5: Food, Beverages & Human Health 23% of sales
Latest results Food, Beverages & Human Health Strong performance, significantly above expectations 2021 perspectives • Organic Q1 sales y/y: 11%. • Food performance driven by innovation and emerging • Performance benefitted from customer stock building, faster markets penetration. emerging market re
Slide 6: Bioenergy 15% of sales
Latest results Bioenergy U.S. ethanol recovery continued but remains affected by 2021 perspectives COVID-19 restrictions • The U.S. ethanol production expected to gradually • Organic Q1 sales y/y: -9%. recover as COVID-19 restrictions are lifted. • U.S. ethanol demand and production remained weak du
Slide 7: Grain & Tech Processing 16% of sales
Latest results Grain & Tech Processing Strong growth, significantly above expectations 2021 perspectives • Organic Q1 sales y/y: 16%. • Growth in grain led by grain milling and vegetable oil • Performance benefitted from customer stock building, faster processing. emerging market recovery, and a bet
Slide 8: Agriculture, Animal Health & Nutrition 13% of sales
Latest results Agriculture, Animal Health & Nutrition Customer stock building benefitted performance above 2021 perspectives expectation • Double-digit underlying growth in agriculture from • Organic Q1 sales y/y: 0%. expansion across crops and regions. • Performance above expectations due to timing
Slide 9: Financials – Performance Q1
Latest results Financials – Performance Q1 Stronger start to the year than expected. 3% organic sales growth and 29.6% EBIT margin • Organic Q1 sales y/y: 3%. DKK sales flat including 3pp net negative impact from currencies and M&A. • Integration of recent Human Health acquisitions progressing well
Slide 10: Outlook 2021
Latest results Outlook 2021 Outlook maintained across key parameters • The better underlying momentum in the first quarter in some businesses does not change the full-year sales outlook due to timing factors, supply-chain volatility and continued COVID-19 related uncertainty. • Organic sales growth
Slide 11: Summary
Latest results Summary Stronger-than-expected start to the year; 3% organic sales growth and strong earnings. 2021 outlook maintained • Better-than-expected performance in the first quarter due to customer stock building, a faster-than- anticipated recovery in emerging markets, and better underlying
Slide 12: Slide 12